[go: up one dir, main page]

NO20091469L - Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer - Google Patents

Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer

Info

Publication number
NO20091469L
NO20091469L NO20091469A NO20091469A NO20091469L NO 20091469 L NO20091469 L NO 20091469L NO 20091469 A NO20091469 A NO 20091469A NO 20091469 A NO20091469 A NO 20091469A NO 20091469 L NO20091469 L NO 20091469L
Authority
NO
Norway
Prior art keywords
disease
treatment
compounds
benzoxazoles
oxazole
Prior art date
Application number
NO20091469A
Other languages
English (en)
Norwegian (no)
Inventor
Marc Gerspacher
Pascal Furet
Eric Wangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091469(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091469L publication Critical patent/NO20091469L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091469A 2006-09-15 2009-04-15 Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer NO20091469L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
PCT/EP2007/007983 WO2008031594A1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Publications (1)

Publication Number Publication Date
NO20091469L true NO20091469L (no) 2009-04-15

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091469A NO20091469L (no) 2006-09-15 2009-04-15 Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer

Country Status (30)

Country Link
US (1) US8629168B2 (pl)
EP (2) EP1900729A1 (pl)
JP (1) JP5325105B2 (pl)
KR (1) KR20090064389A (pl)
CN (1) CN101516860B (pl)
AR (1) AR062786A1 (pl)
AT (1) ATE532774T1 (pl)
AU (1) AU2007296916B2 (pl)
BR (1) BRPI0716841A2 (pl)
CA (1) CA2660987A1 (pl)
CL (1) CL2007002669A1 (pl)
CO (1) CO6150142A2 (pl)
CR (1) CR10639A (pl)
EA (1) EA200900388A1 (pl)
ES (1) ES2377148T3 (pl)
GT (1) GT200900056A (pl)
IL (1) IL196860A0 (pl)
MA (1) MA30723B1 (pl)
MX (1) MX2009002812A (pl)
NO (1) NO20091469L (pl)
PA (1) PA8748101A1 (pl)
PE (1) PE20080842A1 (pl)
PL (1) PL2066647T3 (pl)
PT (1) PT2066647E (pl)
SM (1) SMP200900023B (pl)
TN (1) TN2009000070A1 (pl)
TW (1) TW200819444A (pl)
UY (1) UY30587A1 (pl)
WO (1) WO2008031594A1 (pl)
ZA (1) ZA200900477B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
AU2009270511B2 (en) * 2008-07-15 2013-07-18 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
AR073010A1 (es) * 2008-08-12 2010-10-06 Takeda Pharmaceutical Compuesto amida con actividad agonista del gpr52
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2745004C (en) 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
BR112016017997A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
EP3331851A1 (en) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053479B (en) * 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
BRPI0615449A2 (pt) * 2005-09-02 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst do subtipo 5 e uso desses compostos
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
SMP200900023B (it) 2009-07-14
PL2066647T3 (pl) 2012-04-30
CN101516860B (zh) 2012-06-27
MA30723B1 (fr) 2009-09-01
EA200900388A1 (ru) 2009-08-28
ES2377148T3 (es) 2012-03-22
UY30587A1 (es) 2008-05-02
CO6150142A2 (es) 2010-04-20
TN2009000070A1 (en) 2010-08-19
JP2010503629A (ja) 2010-02-04
JP5325105B2 (ja) 2013-10-23
PA8748101A1 (es) 2009-08-26
US8629168B2 (en) 2014-01-14
PE20080842A1 (es) 2008-08-11
PT2066647E (pt) 2012-01-17
AR062786A1 (es) 2008-12-03
TW200819444A (en) 2008-05-01
IL196860A0 (en) 2009-11-18
CL2007002669A1 (es) 2008-05-09
ZA200900477B (en) 2010-01-27
AU2007296916B2 (en) 2011-10-06
ATE532774T1 (de) 2011-11-15
CA2660987A1 (en) 2008-03-20
EP1900729A1 (en) 2008-03-19
AU2007296916A1 (en) 2008-03-20
CN101516860A (zh) 2009-08-26
CR10639A (es) 2009-07-03
US20100009978A1 (en) 2010-01-14
WO2008031594A1 (en) 2008-03-20
SMAP200900023A (it) 2009-05-11
KR20090064389A (ko) 2009-06-18
GT200900056A (es) 2011-11-08
MX2009002812A (es) 2009-03-31
BRPI0716841A2 (pt) 2013-10-01
EP2066647A1 (en) 2009-06-10
EP2066647B1 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
NO20091469L (no) Benzoxazoler og oxazolpyridiner anvendbare som Janus kinase inhibitorer
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BRPI0809998B8 (pt) composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
TW200615266A (en) Organic compounds
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20073719L (no) Kjemiske forbindelser
NO20055892L (no) Karboksylsyrederivater
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20071109L (no) Indol-2-karboksamidinderivater som NMDA-reseptorantagonister
CN102985553A (zh) 沉默调节蛋白活化剂和活化测定
NO20081369L (no) Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application